TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Hill R, Madureira PA, Ferreira B, Baptista I, Machado S, Colaço L, Dos Santos M, Liu N, Dopazo A, Ugurel S, Adrienn A, Kiss-Toth E, Isbilen M, Gure AO, Link W.
Hill R, et al. Among authors: link w.
Nat Commun. 2017 Mar 9;8:14687. doi: 10.1038/ncomms14687.
Nat Commun. 2017.
PMID: 28276427
Free PMC article.
Retracted.